/
Oncology
Bladder Cancer
137
Pipeline Programs↗
262
Active Trials↗
89
Companies Involved↗
Bladder Cancer is a highly competitive landscape with 137 programs across 89 companies. The most active players are Merck & Co., UroGen Pharma Ltd., Ferring. 38 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical31
Phase 128
Phase 240
Phase 338
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
84 of 116 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 116 classified programs, each share of the total. Modality classified for 93% of 137 pipeline programs.
Analysis
Trial Status
631
clinical trials
Completed206 · 33%
Recruiting124 · 20%
Active, not recruiting83 · 13%
Unknown status69 · 11%
Terminated59 · 9%
Not yet recruiting52 · 8%
Other38 · 6%
Clinical Trials
Trial Activity
631 trials
ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Recruiting·—·Phase 2·NCT06503614·60 enrolled
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Preclinical·NCT06990061·50 enrolled
Page 1 of 43
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)